CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
PF-04217329 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00934089
NCT00934089Phase 2Completed
CompareCT.gov

A Phase 2, Single-masked, Randomized, Crossover Study Of The 24-hour Intraocular Pressure Lowering And Systemic Exposure of Pf-04217329 Alone And In Combination With Latanoprost

Pfizer·interventional·Posted Jul 8, 2009·Updated May 3, 2021

In Brief

A Phase 2 clinical trial evaluating PF-04217329, latanoprost vehicle, and 1 other intervention for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 31 participants across 8 sites.

Detailed Summary

This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients. Blood samples will be collected to measure the amount of active metabolite of PF-04217329 in the plasma following dosing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 8, 2009
Enrollment StartJan 1, 2010
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.0 years ago

Interventions

PF-04217329drug

Topical ocular solution, once-daily for 14 days

latanoprost vehicledrug

Topical ocular solution, once-daily for 14 days

PF-04217329drug

Topical ocular solution, once-daily for 14 days

latanoprostdrug

Topical ocular solution, once-daily for 14 days